Formulary June 2008 BPA Statement

This analysis finds that 57.4 million adults under the age of 65 could potentially be eligible for GLP-1 drugs based on currently approved FDA indications, including 36.2 million people with obesity.

The private-label biosimilar will be available at an 80% discount off Stelara. Evernorth has not released information about which company will be producing the biosimilar.

Outcomes-based agreements can take away clinical uncertainties, so payers have a guarantee that they're not spending money on something that’s not going to work.

The growth of out-of-pocket and insurer/negotiated prices paralleled one another until 2016 when negotiated and insurer prices began declining

Sebetralstat would be the first oral, on-demand treatment for hereditary angioedema if approved.

The new program provides large employers with access to Capital Rx’s technology platform for claim adjudication, invoicing, and reimbursement.